TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating ...

Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close.

Researchers reported that an interim analysis showed DFS favored pembrolizumab (hazard ratio, 0.31), with median DFS not reached in either group.

Global Thrombocytopenia Treatment IndustryThe global Thrombocytopenia Treatment Market is projected to experience significant ...

In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...

Rheumatic heart disease is a serious complication resulting from rheumatic fever, which primarily affects children and young ...

"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

In recent trading, Merck & Co Inc (MRK) stock price has shown some volatility, fluctuating -3.05% over the last five trades and -9.24% over the past 30 trades. This represents a notable shift from ...

Empowering young women with the confidence to excel in their education is key to inspiring the next generation' ...